Relmada Therapeutics (RLMD) Tops Q4 EPS by 5c
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.28), $0.05 better than the analyst estimate of ($1.33).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
- Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
